a cardinal manifestation of CKD. 1 Recent studies have shown that there is a 'U'-shaped relationship between eGFR and risk of all-cause death. Elevated glomerular filtration rate (hyperfiltration) is observed in patients with hypertension, type 1 and type 2 diabetes, and is also seen in patients with pre-diabetes conditions, such as metabolic syndrome. Both vascular and tubular factors likely contribute to the pathogenesis of hyperfiltration. Hyperfiltration is hypothesized to be a precursor of intraglomerular hypertension leading to albuminuria. Persistent hyperfiltration is an independent risk factor for accelerated renal function loss and development or progression of nephropathy. 2 A recent meta-analysis demonstrated that when the eGFR was >105 ml/min/1.73m 2 there was an increased risk of cardiovascular mortality, coronary heart disease (CHD), stroke, and heart failure, which was especially evident in individuals with diabetes and hypertension. 3 A prospective cohort study showed that an eGFR of 90-119 ml/min alone was associated with a 72% increase in overall mortality and when coupled with albuminuria (albumin-to-creatinine [ACR] 80 mg/g), it soared to 395%. 4 These findings provide strong evidence that hyperfiltration is a pathologic state-an increase in eGFR from baseline rather than a 'healthy' eGFR.
Albumin-to-creatinine ratio
So, what is albuminuria? An elevated urinary albumin excretion is a marker of endothelial dysfunction that symbolizes the kidney's way to translate the existence of vascular damage. Albuminuria is an independent risk factor for progression of CHD and stroke in men and women with diabetes or hypertension, the general population, and those with established CHD. 5 The American Diabetes Association (ADA) and the National Kidney Foundation define an ACR <30 mg/g as normal albuminuria, between 30 and 300 mg/g as microalbuminuria, and >300 mg/g as macroalbuminuria, in both men and women. These definitions do not take into account sex differences in creatinine excretion, and several researchers have advocated sex-specific cut-off points of the ACR. Three landmark studies, the Losartan Intervention for Endpoint (LIFE) study, the Heart Outcomes Prevention Evaluation (HOPE) study, and the Nord-Trøndelag Health (HUNT II) study showed that increased albumin excretion, even at nearly 'normal' levels were associated with increased CHD mortality and stroke. An ACR >5 mg/g increases cardiovascular mortality, heart failure, CHD, and stroke. 6 The risk gradient was steeper for cardiovascular mortality and heart failure than for CHD and stroke, a pattern consistent with other studies. 3 The Framingham Heart Study showed a threefold risk for developing CHD when the ACR was >3.9 mg/g in men and >7.5 mg/g in women. 7 This growing body of evidence challenges the notion that ACR <30 mg/g indicates 'normal' albumin excretion. inhibition preserves renal function by decreasing albuminuria, leading to a decrease in blood pressure and arterial stiffness, and ultimately decreasing the risk of cardiovascular events and hospitalization for heart failure. 11 The effects of GLP-1 agonist therapy are reminiscent of known effects of a renin-angiotensin-aldosterone system blocking treatment, which in several studies has been shown to reduce albuminuria and GFR in type 2 diabetes. while these clinical trials-as well as many other studies-looked at reductions in albuminuria, the primary outcomes were not designed to study this relationship. The major focus, especially in these three studies, was major adverse cardiovascular events such as cardiovascular death, non-fatal MI, and non-fatal stroke (3-MACE). Future study designs must look at albuminuria as a primary end-point to prove (of refute) the validity of albuminuria as a target in reducing CHD and stroke.
GLP-1 inhibits angiotensin II and its pro-inflammatory effects
In conclusion, eGFR (low and hyperfiltration) and albuminuria independently improved cardiovascular prediction, particularly for cardiovascular mortality and heart failure. ACR outperformed eGFR and most of the modifiable traditional risk factors for these two outcomes, as well as stroke, supporting its use for cardiovascular risk assessment in a broad range of settings. Among clinical populations, in which the assessment of eGFR and albuminuria is already recommended (e.g., for individuals with CKD, diabetes, or hypertension), these measures of kidney disease are especially useful for prediction of cardiovascular risk. An accepted definition of the diagnosis of hyperfiltration is necessary as well as good markers of kidney function to study patients within the hyperfiltration range. Furthermore, it is imperative that health professionals understand that albuminuria is an independent risk factor for CHD and at levels that appear to be well below current guidelines. This is further substantiated by a very recent study that showed ACR below 30 mg/g is a predictor of incident hypertension and cardiovascular mortality. 13 
